We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan and Biocon Hit With Second CRL for Insulin Glargine Biosimilar
Mylan and Biocon Hit With Second CRL for Insulin Glargine Biosimilar
The FDA has again shot down Mylan and Biocon’s copycat of Sanofi’s Lantus (insulin glargine) with a complete response letter, pending the completion of corrective actions at Biocon’s Malaysian insulin plant.